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Abstract:  
 
Objectives: Patient global assessment (PGA) is included in almost all rheumatoid arthritis (RA) 
composite disease activity indices and definitions of remission. However, different PGA 
formulations exist and are used interchangeably in research and clinical practice. We 
investigated how five different PGA formulations used in four disease indices affect the 
remission rates. 
 
Methods: This was an ancillary analysis of data from a cross-sectional study in patients with 
RA. The data comprised: 28-joint counts, C-reactive protein and five PGA formulations. 
Remission rate variation was assessed using five PGA formulations in each index 
(ACR/EULAR Boolean, CDAI, SDAI and DAS28-CRP). PGA agreement were assessed by: 
Pearson's correlation; Bland-Altman plots; paired samples t-test; establishing the proportion of 
patients who scored (i) all formulations within an interval of 20mm, and (ii) each formulation 
≤10mm.  
 
Results: This analysis included 191 patients. PGA formulations presented good correlations 
(≥0.65) but Bland-Altman plots showed clinically significant differences, which were 
statistically confirmed by comparison of means. Just over a half (51.8%) of patients scored all 
PGA formulations within a 20mm interval. The proportion of those scoring ≤10mm varied from 
11.5% to 16.2%. When different formulations of PGA were used in each index, remission 
differences of up to 4.7%, 4.7%, 6.3%, and 5.2% were observed. When formulations were used 
in their respective indices, as validated, the remission rates were similar (13.1%, 13.6%, 14.1%, 
and 18.3%). 
 
Conclusions: Using PGA formulations interchangeably may have implications in the 
assessment of disease activity and in the attainment of remission and this can impact upon 
management decisions.  
 
Keywords: Rheumatoid Arthritis, Patient Reported Outcome Measures, Remission Induction, 
Patient Preference; Disease activity; Patient Global Assessment 
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Introduction  
 In the last two decades, significant advances have been observed in the treatment of 
rheumatoid arthritis (RA) as a result not only of the introduction of new therapies but also of 
new strategies, such as “treat-to-target” (T2T)[1]. Remission, or at least low disease activity 
(LDA) has become a consensual guiding target for therapy[2-4], as this provides the best 
assurance of good structural and functional outcomes[5]. Thus, the assessment of disease 
activity is crucial and the use of combined indices and their cut-offs is recommended to guide 
and evaluate treatment options, both in research and in clinical practice[2-4]. 
 However, a “gold standard” definition of remission has not been established[2]. The 
four commonly used definitions are: Disease Activity Score 28 (DAS28)-based remission[4,6], 
the American College of Rheumatology (ACR)/ European League Against Rheumatism 
(EULAR) Boolean-based remission, the Clinical Disease Activity Index (CDAI)-based 
remission, and the Simplified Disease Activity Index (SDAI)-based remission, the last two have 
been elected as preferential[2,3]. Not surprisingly, different criteria provide different rates of 
remission[7]. 
 Patient global assessment (PGA) is the only patient-reported outcome (PRO) included 
in all of the above-mentioned disease activity indices, and considerable attention has been paid 
recently to its influence on remission rates[8-10]. Several limitations have been pointed out to 
this assessment, including variations in the: (i) phrasing of the question (e.g. "disease", 
"arthritis", or "health"; (ii)  phrasing of the anchors (e.g. "very well" or "the best"); (iii) type of 
rating scale (e.g. visual analogue scale (VAS) with 10cm or numeric rating scale (NRS) from 0 
to 10); and (iv) time intervals to which the evaluation refers (e.g. "last week" or "today")[10,11]. 
Despite these observations, the different formulations of PGA seem to be used indistinctly in 
both clinical practice and in research[10]. 
This study aimed at: (i) evaluating if and how the score of PGA by patients with RA 
differs according to the formulation of the question, and (ii) assessing the influence of this 
variability upon remission and LDA rates obtained with four different indices. 
 
Participants and Methods 
Study design & setting 
This was an ancillary analysis of data from an observational, cross-sectional study, 
performed in a single rheumatology outpatient department[9]. 
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Participants 
The original study included consecutive adult patients with a definite diagnosis of RA 
(ACR 1987 revised criteria or ACR/EULAR 2010 classification criteria). Patients were 
excluded if they declined participation or if they were unable to respond to the questionnaires 
unaided. Ethical approval was granted by the Ethics Committee of the Faculty of Medicine, 
University of Coimbra (CE-037/2015). All patients signed consent according to the Declaration 
of Helsinki. Additional consent for this ancillary study was not required. Here, data was 
included from patients who had completed the five versions of PGA and had information for 
all disease activity indices. 
 
Patient global assessment 
All patients assessed their PGA using the following different formulations:  
 “Considering all the ways your arthritis has affected you, how do you feel your arthritis 
is today?” as recommended by ACR/EULAR[2] (v1). 
  “Considering all the ways your arthritis affects you, rate how well you are doing on 
the following scale” - as in CDAI and SDAI[12] (v2) 
 “How well do you consider your health status during the past week?”- as in the original 
DAS28[13] (v3) 
 “How active was your arthritis during the past week?” - as by current DAS28[13] (v4) 
 “Your disease has ups and downs. When it is very active (“alight”, “scalded/hot”), 
there is more pain, morning stiffness, joint swelling and tiredness. Taking this into 
account, how would you rate the state of your disease over the last week?” - PGA 
formulated by investigators (v5). 
All formulations were presented as a 0-100 mm, unmarked, horizontal VAS, with their 
respective anchors. 
 
Other Variables 
Questionnaires included patient demographic data and other PROs, as described 
elsewhere[9]. The attending physician provided: tender 28-joint count (TJC28), swollen 28-
joint count (SJC28), C-reactive protein (CRP) and Physician Global Assessment (PhGA). 
Each formulation of PGA was presented in a single page of the questionnaire, 
interspersed with other PROs to serve as “distractors”[11] and these were completed before 
clinical consultations. 
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Disease activity indices 
The following disease activity indices and respective cut-off points were used to assess 
remission: (i) ACR/EULAR Boolean-based definition of remission: TJC28, SJC28, CRP (in 
mg/dl) and PGA (in cm) all≤1[2],  (ii) SDAI≤3.3[12],  (iii) CDAI≤2.8[12], and (iv) DAS28-
CRP<1.9[6]. Cut-offs for LDA state were: SDAI≤11[12], CDAI≤10[12], and DAS28-
CRP≤3.1[6].  
 
Statistical methods 
Differences across the five PGA formulations were assessed by: (i) Pearson's correlation 
coefficients, (ii) Bland-Altman plots (with limits of agreement of 1.96×SDmean difference)[14], 
using the ACR/EULAR formulation (v1) as the reference (defined a priori, based on results of 
a systematic review[10]), (iii) paired samples t-test, comparing the mean scores obtained with 
each formulation, (v1 used as reference); (iv) examining the proportion of patients who scored 
all PGA formulations within an interval of 20mm, (v) comparing the proportion of patients who 
scored each formulation ≤10mm; (vi) comparing the proportion of patients classified as in 
remission (and in LDA) according to each formulation; Chi-square test was used to test this 
difference, namely using indices with their assigned PGA formulation.  
 
Results 
Patient characteristics 
A total of 191 patients were included in this analysis. The demographic and clinical 
characteristics are presented in Supplementary Table S1. Eighty-three percent of the 
participants were female, with mean (SD) age:  59(13) years, disease duration: 12(9) years and 
DAS28-CRP3v: 2.5(1.0). Thirty-four percent were on biologic disease-modifying 
antirheumatic drugs (bDMARDs). 
 
Differences between PGA formulations 
 The correlations between PGA formulations were all good, varying from rp=0.65 to 
rp=0.80 (all p<0.001) (Supplementary Table S2).  
The Bland-Altman plots showed low agreement between formulations, with 95% limits 
of variability ranging from [-37.8 to +30.4mm (v2 vs v1)] to [-49.7 to 40.9mm (v5 vs v1)] 
(Supplementary Figure S1). 
 When comparing mean scores, the two DAS28 formulations obtained the lowest 
average scores (42.9mm and 42.3mm, respectively). In contrast, the formulations created by 
the investigators and the SDAI/CDAI resulted in the highest mean scores (48.1mm and 
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47.2mm, respectively), presenting a statistically significant difference (p=0.0003 and p=0.006, 
respectively) when compared with the reference (Table 1).   
 Ninety-nine patients (51.8%) responded to all five formulations within an interval of 
20mm. The ACR/EULAR formulation had the largest number of patients scoring ≤10mm 
(16.2%), while the investigator’s and the SDAI/CDAI formulations presented the lowest 
proportions (11.5% and 12.0%, respectively) (Table 1).  
 
Differences in Remission rates according to PGA formulations 
 When the proper formulations were used in their respective indices, the remission rates 
were similar in three disease activity indices: 13.1%, 13.6%, and 14.1%, respectively for 
ACR/EULAR Boolean criteria (using v1), CDAI (using v2) and SDAI (using v2). The 
percentage of patients classified in remission with the DAS28-CRP (using v4) was slightly 
higher (18.3%) (Figure 1). Chi-square test revealed, statistically significant differences across 
all these proportions (Table 2). 
 When assessing the use of the different formulations in different indices, we observed 
that the ACR/EULAR formulation was associated with the highest rate of remission in all the 
four indices. Conversely, the SDAI/CDAI and the Investigator's formulations were associated 
with the lowest remission rates. The maximum differences in rates of remission with the same 
index depending on the PGA formulation used (highest minus lowest) were: 4.7% 
(ACR/EULAR Boolean-based), 4.7% (SDAI), 6.3% (CDAI), and 5.2% (DAS28-CRP) (Figure 
1). Considering the patients that reached at least LDA, the maximum differences between 
formulations ranged from 2.6% to 4.8% according to the index used (Table 3). 
 
Discussion 
 This study tested how the PGA scored by individual patients with RA varies according 
to 5 different formulations of this question. We assessed the impact of these formulations upon 
the rates of remission and LDA defined by different disease indices. These issues have a direct 
impact upon treatment decisions, according to current recommendations. Although the 
Pearson's correlations among these formulations were good, the comparison of PGA means 
values showed statistically significant differences. The 95% limits of variability revealed by 
the Bland-Altman plots would probably be considered as relevant by most practicing clinicians. 
Only approximately half of patients (51.8%) scored the five PGAs within a 20mm interval. 
More importantly, differences in remission rates using different formulations of PGA for the 
same index were significant: for instance, ACR/EULAR Boolean-based remission varied 
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between 8.4% to 13.1% only by switching between the five versions of PGA; this difference 
was highest using CDAI, with remission rates varying 13.6% and 19.9%. 
 Even though PGA has been widely employed in RA research[10], only few 
studies[11,15-17] have examined the effect of using different formulations in the assessment of 
disease activity status. The main conclusions have been, largely, similar in three of these 
studies[15-17]: although the formulations "are individually not equivalent, they may be used 
interchangeably for calculating composite indices"[17]. French et al.[11] suggested caution on 
this interchangeable use of formulations and advocated standardization of PGA. The above 
studies tested two[16,17], three[15], or five[11] PGA formulations, that resulted in maximum 
discrepancies in the remission rates of 0.5%[17], 0.9%[15], 1.3%[16], and 4.0%[11] using 
DAS28, 1.0% using CDAI[17], and 0.4% using Routine Assessment of Patient Index Data 3 
(RAPID3)[17], Our study presented higher percentages of variation between formulations: 
5.2% for DAS28 and 6.3% for CDAI. The main characteristics and results of the previous and 
present study are summarised in Supplementary Table S3. 
The above-mentioned discrepancy between individual study results may be related to 
different factors, with emphasis on the phrasing of the formulations. In our study, asking "(...) 
how do you feel your arthritis is today?" (as in ACR/EULAR) led to the highest percentage of 
remission. However, using a very similar formulation (as in SDAI/CDAI), but without a 
reference period, the opposite effect was observed. In a qualitative study from our group[18], 
many patients preferred being asked "today" instead of "last week" because it is easier to recall 
the symptoms and scoring them. It was rather surprising that the PGA formulation created by 
the investigators, using a more detailed and culturally adapted explanation was the one with the 
highest mean value and with fewer patients scoring ≤10mm. A possible explanation was the 
inclusion of "fatigue", which patients might not otherwise consider a manifestation of RA[8]. 
Secondly, when using the DAS28, the effect of different PGA formulations is negligible, mostly 
because of the limited weight that is given to this component[16]. Finally, the levels of disease 
activity of the samples (influenced by the study design, among other factors) may have 
influenced the discrepancies, as higher levels of disease activity may be expected to be 
associated with larger differences between PGA formulations[16]. Our results, however, 
contradict this assumption given that our sample presented near half levels of disease activity 
but much higher discrepancies compared with previous studies (Supplementary Table S3). This 
suggests that culture and educational levels may play an important role in these assessments 
and these influences should not be ignored[19].  
One possible limitation of this study is: the use of VAS instead of NRS in the 
SDAI/CDAI formulation. Use of VAS (rather than NRS) helped to standardise measures, and 
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evidence from previous studies[19,20] suggest that this would not change our conclusions. 
Another limitation was the presentation of formulations in the same sequence to all patients, 
although they were interspersed with other scales. 
 Some important strengths of our study include (i) the use of four disease activity indices 
and four commonly used PGA formulations  (ii) this was the first study to access the influence 
of the proper PGA formulations in the respective indices (iii) using the updated cut-offs for the 
DAS28-CRP[6], which allow for a better comparison between the indices and (iv) recruitng 
patients from clinical practice rather than using data from a clinical trial, as PGA instructions 
and interpretation by patients may be different in both contexts.  
 Although the added value of including PGA in the definition of disease activity 
remission is being debated[21,22], it seem unequivocal, in face of our results, that each 
formulation of PGA should be limited to the respective disease activity index or, perhaps ideally 
that the PGA formulation should be standardized into a unique format. 
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Fig 1 Remission rates according to four disease activity indices using five different 
formulations of Patient Global Assessment (n=191). The arrows represent the remission rate 
measured by a disease activity index with its respective PGA formulation.  
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Table 1. Comparison of different PGA formulations with ACR/EULAR version as reference (n=191) 
Characteristics of the formulations 
 Comparison of mean PGA 
scores 
n (%) of 
patients 
scoring PGA 
≤10 mm 
Source  Phrasing 
Reference 
period 
Anchors a 
 
Mean (SD) p-value c 
v1. ACR/EULAR 
“Considering all the ways your arthritis has affected 
you, how do you feel your arthritis is today?” 
Today 
“Very well” and 
“Very poor” 
 
43.5 (28.0) reference 31 (16.2) 
v2. SDAI/CDAI 
“Considering all the ways your arthritis affects you, 
rate how well you are doing on the following scale” 
Unspecified 
time period 
“Very well” and 
“Very poor” 
 
47.2 (26.0) 0.003 23 (12.0) 
v3. DAS original 
(GH) 
“How well do you consider your health status 
during the past week?” 
Last week 
“The best” and 
“The worst” 
 
42.9 (25.3) 0.697 27 (14.1) 
v4. DAS current 
(DA) 
“How active was your arthritis during the past 
week?” 
Last week 
“Not active at all” and 
“Extremely active” 
 
42.3 (25.5) 0.400 28 (14.7) 
v5. PGA 
formulated by the 
investigators 
“Your disease has ups and downs. When it is very 
active (“alight”, “scalded/hot”), there is more pain, 
morning stiffness, joint swelling and tiredness. 
Taking this into account, how would you rate the 
state of your disease over the last week?” b 
Last week 
“Not active at all” and 
“Extremely active” 
 
48.1 (26.8) 0.006 22 (11.5) 
ACR/EULAR: American College of Rheumatology/European League Against Rheumatism; SDAI/CDAI: clinical disease activity index/simplified disease activity index; DAS: 
disease activity score; GH: general health; DA: disease activity; PGA: patient global assessment  
 a. All formulations were assessed with horizontal, unmarked visual analogue scales (0-100mm).  
b. In Portuguese: “A sua doença tem altos e baixos. Quando está muito ativa (“acesa”, “assanhada”) há mais dor, prisão pela manhã, inchaço e cansaço. Tendo isto em conta, como 
classificaria o estado da sua doença na última semana?”   
c. Paired sample t-test using, as pre-defined, taking the ACR/EULAR formulation as reference. 
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Table 2. Comparison of the proportion of patients in remission between disease activity indices 
using their respective Patient Global Assessment formulations (n=191) 
  
ACR/EULAR Boolean-Based 
(using v1) 
Chi-square 
test 
p-value 
  Non-Rem. Remission Total 
SDAI  
(using v2) 
Non-Rem. 156 8 164 
68.757 <.001 Remission 10 17 27 
Total 166 25 191 
CDAI  
(using v2) 
Non-Rem. 156 9 165 
62.104 <.001 Remission 10 16 26 
Total 166 25 191 
DAS28-CRP a 
(using v4) 
Non-Rem. 146 10 156 
33.381 <.001 Remission 20 15 35 
Total 166 25 191 
ACR: American College of Rheumatology; CDAI: clinical disease activity index; DA: Disease Activity; DAS28-
CRP: disease activity score 28-joint count using C-Reactive Protein; EULAR: European League Against 
Rheumatism; GH: Global Health; PGA: patient global assessment; SDAI: simplified disease activity index. 
a. Fleishman's et al.[6] cut-off: remission<1.9 
Figures in bold represent the discordant classification between disease activity indices. 
 
Table 3. Proportion of patients in remission and low disease activity states according to the 
Patient Global Assessment formulations across different clinical disease activity indices 
(n=191). Values represent n (%). 
Disease Activity 
Indices 
Disease Activity 
Status 
PGA Formulations 
v1 
ACR/EULAR 
v2 
SDAI/CDAI 
v3 
DAS28-GH 
v4 
DAS28-DA 
v5 
Investigator's 
ACR/EULAR 
Boolean-Based 
Remission a 25 (13.1) 16 (8.4) 20 (10.5) 19 (9.9) 17 (8.9) 
SDAI 
Remission 36 (18.8) 27 (14.1) 29 (15.2) 29 (15.2) 27 (14.1) 
LDA 102 (53.4) 107 (56.0) 109 (57.1) 112 (58.6) 106 (55.5) 
Rem. + LDA 138 (72.2) 134 (70.1) 138 (72.3) 141 (73.8) 133 (69.6) 
CDAI 
Remission 38 (19.9) 26 (13.6) 33 (17.3) 30 (15.7) 27 (14.1) 
LDA 100 (52.4) 108 (56.5) 109 (57.1) 113 (59.2) 106 (55.5) 
Rem. + LDA 138 (72.3) 134 (70.1) 142 (74.4) 143 (74.9) 133 (69.6) 
DAS28-CRP b 
Remission 42 (22.0) 34 (17.8) 33 (17.3) 35 (18.3) 32 (16.8) 
LDA 91 (47.6) 102 (53.4) 103 (53.9) 101 (52.9) 99 (51.8) 
Rem. + LDA 133 (69.6) 136 (71.2) 136 (71.2) 136 (71.2) 131 (68.6) 
ACR: American College of Rheumatology; CDAI: clinical disease activity index; DA: Disease Activity; DAS28-
CRP: disease activity score 28-joint count using C-reactive protein; EULAR: European League Against 
Rheumatism; GH: Global Health; LDA: Low Disease Activity; PGA: patient global assessment; SDAI: simplified 
disease activity index. 
a. Low disease activity is not applicable to this definition. 
b. Fleishman's et al. [6] cut-offs: remission<1.9 and LDA≤3.1  
Figures in bold represent the higher percentages (per line) and the underlined represent the lowest percentages.
  
SUPPLEMENTARY MATERIAL of 
Influence of the different “patient global assessment” formulations on disease activity 
score by different indices in Rheumatoid Arthritis. Ferreira RJO, Eugénio G, Ndosi M, Silva 
C, Medeiros C, Duarte C, da Silva JAP 
Contact: ferreira.rjo@gmail.com 
 
Supplementary Table 1. Demographic and clinical characteristics of RA patients (n=191).  
Variable mean (SD) n (%) 
Age, years 59.1 (12.9)  
Number of women  158 (82.7) 
Years of formal education 7.5 (4.8)  
Disease duration in years 12.4 (9.4)  
Treated with biologic agents  65 (34.2) 
TJC28 (0–28) 1.5 (3.3)  
SJC28 (0–28) 1.6 (2.8)  
CRP (mg/dl) 0.8 (1.5)  
PhGA (VAS, 0-100) 13.3 (15.9)  
HAQ (0–3) a 1.1 (0.7)  
DAS28-CRP (3v) 2.5 (1.0)  
SJC28: swollen 28-joint count; TJC28: tender 28-joint count; CRP: C-reactive protein; PhGA: physician global 
assessment; VAS: visual analogue scale; HAQ: health assessment questionnaire; DAS28: disease activity score 
with 28-joint counts. 
a. Missing data in 2 (1.0%) patients. 
 
  
Supplementary Table S2. Pearson’s correlations across the five formulations of Patient Global 
Assessment (n=191). All correlations were significant at p<0.001 
 
v2 
SDAI/CDAI 
v3 
DAS28-GH 
v4 
DAS28-DA 
v5 
Investigator's 
PGA 
v1 ACR/EULAR .80 .71 .75 .65 
v2 SDAI/CDAI  .67 .72 .69 
v3 DAS28-GH   .76 .65 
v4 DAS28-DA     .65 
ACR: American College of Rheumatology; CDAI: clinical disease activity index; DA: Disease Activity; DAS28: 
disease activity score 28-joint count; EULAR: European League Against Rheumatism; GH: Global Health; PGA: 
patient global assessment; SDAI: simplified disease activity index. 
 
  
Supplementary Figure S1 - Bland-Altman plots for agreement (in mm) between ACR/EULAR 
formulation and the other four Patient Global Assessment formulations (n=191).  
 
 
ACR: American College of Rheumatology; CDAI: clinical disease activity index; DA: Disease Activity; DAS28: 
disease activity score 28-joint count; EULAR: European League Against Rheumatism; GH: Global Health; PGA: 
patient global assessment; SDAI: simplified disease activity index. 
Footnote: The solid line in each plot represents the mean of the difference between the two PGA formulations. The 
dashed lines demarcate the upper and lower 95% limits of agreement between them, which were determined by 
multiplying the standard deviation (SD) of the mean difference by 1.96. In all plots, the 95% limits of agreement 
are considered clinically relevant., using our clinical judgements and published criteria (11, 16). 
 
  
Supplementary Table S4. Main characteristics and results of studies testing the influence of different formulations of Patient Global Assessment or 
remission rates  
Study Patients Disease PGAs Influence in remission rates 
1st author 
(year), 
Country 
Design/ 
Analysis 
n 
Mean 
(SD) 
Age 
% 
Fema-
les 
Educa-
tional 
level  
Disease 
Dura-
tion 
% 
treated 
biologics 
Mean (SD) 
Disease 
activity 
Concepts 
Reference 
Period 
Scoring 
Method 
(Left/ Zero) Anchors DAI used Min.** Max. 
Koevoets 
(2011),  
The 
Netherlands 
RCT/ Long. 
(1year) 
467 NA NA NA 
100% 
<2y 
100%* 
DAS 
Baseline#:  
4.4 (0.9) 
1) Global Health1 
2) Disease Activity2 
NA NA NA 
a) DAS 
b) 6 DAS 
variations 
c) DAS28 
** 
a) 0.4% 
b) 0.2 to 
1.6% 
c) 1.3% 
Dougados 
(2011), 
France and 
Monaco 
RCT/ 
Long. 
(12wks) 
108 54 (13) 75% NA 8 (7) 100%* 
DAS28(4v) 
Baseline#: 
5.4 (0.8) 
1) Global Health3 
2) Disease Activity4 
3) Disease Impact (by RAID)5 
1) Last 2-3 weeks 
2) Last 48 hours 
3) Last 8 days 
NRS  
0-10 
NA a) DAS28 a) 0.0%  a) 0.9% 
Khan 
(2012),  
30 
Countries 
Observ./ 
Cross-
sectional 
7023 55 (13) 80% 
34% 
>12y 
11 (10) NA 
DAS28: 
 4.3 (1.7) 
1) Joint tenderness and Swelling6 
2) Global Illness and Health7 
1) Today 
2) At this time 
VAS  
0-10cm 
1) Not active 
2) Very well 
a) DAS28 
b) CDAI 
c) RAPID3 
** 
a) 0.5% 
b) 1.0% 
c) 0.4% 
French 
(2013),  
The UK 
Observ./ 
Cross-
sectional 
50 58 (14) 78% NA 16 (9) 92%¶ 
DAS28(4v):  
4.3 (1.5) 
1) Feeling (concerning arthritis)8 
2) Disease Activity9 
3) Well-Being10 
4) Best/Worst11 
5) All ways arthritis affect you12 
1) Last week 
2) This week 
3) This week 
4) Last week 
5) No reference 
VAS  
0-100mm 
1) Very well 
2) Not active at all 
3) Best imaginable health  
4) Best have ever been 
5) Very well 
a) DAS28 a) 0.0%¶ a) 4.0%¶ 
Present  
Study  
Observ./ 
Cross-
sectional 
191 59 (13) 83% 
15% 
>12y 
12 (9) 34% 
DAS28(3v):  
2.6 (1.2) 
DAS28(4v): 
2.9 (1.3) 
1) Feeling (concerning arthritis) 13 
2) How arthritis affect you14 
3) Global Health15 
4) Arthritis activity16 
5) Disease (ups & downs) 
activity17 
1) Today 
2) No reference 
3) Last week 
4) Last week 
5) Last week 
VAS  
0-100mm 
1) Very well 
2) Very well 
3) The best 
4) Not active at all 
5) Not active at all 
a) ACR/EULAR 
Boolean-based 
b) SDAI 
c) CDAI 
d) DAS28¶¶ 
 
a) 0.5% 
b) 0% 
c) 0.5% 
d) 0.5% 
 
a) 4.7% 
b) 4.7% 
c) 6.3% 
d) 5.2%¶¶¶ 
ACR/EULAR: American College of Rheumatology/European League Against Rheumatism; CDAI: clinical disease activity index; DAS: disease activity score; DAS28: disease 
  
activity score 28-joint count; NA: Non-available: PGA: patient global assessment; RAID: Rheumatoid Arthritis Impact of Disease; RAPID3: Routine Assessment of Patient Index 
Data 3; RCT: Randomized Controlled Trial; SDAI: simplified disease activity index. 
* At the time of the analysis (i.e. at 1 year and 12 weeks, respectively); ** Applicable when 3 or more formulations were tested; ¶ Authors reported a maximum difference of 0.63 
points in DAS28 in the paper but kindly provided the database to us in order to calculate these rates; ¶¶ Using Fleishman's et al.(6) cut-off: remission<1.9; ¶¶¶ If using the same cut-
off of other studies (rem<2.6) the variation is the same # DAS28 values not provided for the follow-up periods (i.e. at 1 year and 12 weeks, respectively). 
1 - Authors do not specify the wording in the manuscript. 
2 - Authors do not specify the wording in the manuscript. 
3 -  "In general, how would you rate your health over the last 2–3 weeks?" 
4 -  “Please estimate your disease activity over the last 48 hours” 
5 - The "Rheumatoid Arthritis Impact of Disease" score was used, which results from a weightned mean of 7 disease impact domains, ranging from 0 to 10. 
6 -  "In therms of joint tenderness (ie, joint pain associated with light touch) and joint swelling (ie, joint enlargment due to inflmation), how active would you say your rheumatic 
condition is TODAY?" 
7 - "Considering all the ways in which illness and health conditions may affect you at this time, please make a mark below to show how you are doing" 
8 - " How do you feel concerning your arthritis over the last week?" 
9 -  "How active has your disease been this week?" 
10 -  "How has your overall well-being been this week?" 
11 -  "If 0 is the best you have ever been and 100 is the worst you have ever been, where do you think you have been over the last week?" 
12 -  "Considering all the ways your arthritis affect you mark on the line bellow how well you are doing." 
13 - “Considering all the ways your arthritis has affected you, how do you feel your arthritis is today?” 
14 - “Considering all the ways your arthritis affects you, rate how well you are doing on the following scale” 
15 - “How well do you consider your health status during the past week?” 
16 - “How active was your arthritis during the past week?” 
17 - “Your disease has ups and downs. When it is very active (“alight”, “scalded/hot”), there is more pain, morning stiffness, joint swelling and tiredness. Taking this into account, 
how would you rate the state of your disease over the last week?” 
 
